Meta-analysis fever in the wake of CARAVAGGIO
The CARAVAGGIO clinical trial has clearly been a landmark study that established the important role for direct oral anticoagulants (DOACs), especially apixaban as a treatment for venous thromboembolism (VTE) in cancer [1]. The study clearly showed that apixaban was non-inferior to subcutaneous dalteparin for the treatment of cancer associated VTE without an increased risk of major bleeding.
Source: Thrombosis Research - Category: Hematology Authors: Tarek Haykal, Soheir Adam, Thomas L. Ortel Tags: Editorial Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Clinical Trials | Hematology | Oral Cancer | Study | Thrombosis